pegademase bovine (Adagen)

Indications

• enzyme replacement therapy for patients with severe combined immunodeficiency disease (SCID) due to adenosine deaminase (ADA) deficiency

Dosage

• dosage individualized based on monitoring of plasma ADA activity
• weekly IM administration

Injection: 250 units/mL

Pharmacokinetics

• peak plasma levels of ADA activity reached 2-3 days following IM administration
• plasma elimination half-life of ADA following IM administration of Adagen is 3 to > 6 days

Mechanism of action

• (monomethoxypolyethylene glycol succinimidyl) 11-17- adenosine deaminase
• conjugate of numerous strands of monomethoxypolyethylene glycol covalently attached to the enzyme adenosine deaminase

More general terms

• metabolic agent (metabolic modifier)